Panblok H7/MF59 influenza vaccine / Sanofi - LARVOL DELTA

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older (clinicaltrials.gov) - P1/2 | N=581 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed | Phase classification: P2 ➔ P1/2

Phase classification • Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older (clinicaltrials.gov) - P2 | N=581 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older (clinicaltrials.gov) - P2 | N=700 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older (clinicaltrials.gov) - P2 | N=700 | Not yet recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases